Acer Therapeutics Inc. (ACER) Bundle
A Brief History of Acer Therapeutics Inc. (ACER)
Foundation and Initial Focus
Acer Therapeutics Inc. was founded in 2013, with a primary focus on developing therapies for rare diseases. The company emerged from a vision to address unmet medical needs in the treatment of serious and rare conditions.
Key Developments
In 2017, Acer went public, raising approximately $25 million through an initial public offering (IPO) at a price of $8.00 per share. The company utilized these funds to advance its pipeline of drug candidates.
Lead Product Candidate: ACER-001
ACER-001, a formulation of sodium phenylbutyrate, is Acer's leading product candidate. It targets urea cycle disorders (UCDs) and has been pivotal in the company's strategy. In March 2020, Acer announced that the U.S. FDA granted Orphan Drug Designation for ACER-001 for the treatment of UCDs.
Financial Overview
As of Q2 2023, Acer Therapeutics reported total revenue of $2.5 million, mainly attributed to research collaborations. The company's operating expenses for the same period were approximately $6.1 million. This led to a net loss of $3.6 million.
| Financial Metric | Q2 2023 | Q1 2023 | Q2 2022 |
|---|---|---|---|
| Total Revenue | $2.5 million | $3.0 million | $4.5 million |
| Operating Expenses | $6.1 million | $5.8 million | $5.4 million |
| Net Loss | $3.6 million | $2.8 million | $0.9 million |
| Cash and Cash Equivalents | $10.2 million | $8.1 million | $15.0 million |
Regulatory Milestones
In August 2020, Acer submitted a New Drug Application (NDA) to the FDA for ACER-001. The application sought approval for the treatment of UCDs. In April 2021, the FDA accepted the NDA and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 2022.
Collaborations and Partnerships
Acer has engaged in several collaborations to enhance its research and development capabilities. Among these was a partnership with the National Institutes of Health (NIH) in 2021 to explore new indications for ACER-001.
Market Performance
As of October 2023, Acer Therapeutics' stock price was approximately $1.15, reflecting a market capitalization of about $30 million. The stock has shown volatility, trading between $0.90 and $1.50 in the preceding year.
Future Prospects
The company continues to focus on advancing the development of ACER-001 while exploring additional therapeutic areas. Analysts project that once approved, ACER-001 could capture a significant share of the UCD market, estimated to be valued at over $500 million annually.
Conclusion of Historical Data
Acer Therapeutics Inc.'s journey reflects its commitment to addressing rare diseases through innovative therapeutic solutions. The ongoing developments and potential market impact of its lead candidates will remain a focal point for investors and stakeholders alike.
A Who Owns Acer Therapeutics Inc. (ACER)
Current Shareholder Structure
Current Shareholder Structure
The ownership of Acer Therapeutics Inc. (ACER) is composed of various institutional and retail investors. The following table summarizes the major shareholders as of the latest data available in 2023.
| Shareholder Type | Name | Percentage Ownership | Number of Shares |
|---|---|---|---|
| Institutional Investors | BlackRock, Inc. | 7.5% | 1,500,000 |
| Institutional Investors | The Vanguard Group, Inc. | 6.3% | 1,260,000 |
| Institutional Investors | Opus Point Partners Management, LLC | 5.2% | 1,040,000 |
| Insider Ownership | Dr. Chris D. Prior (CEO) | 3.5% | 700,000 |
| Insider Ownership | David A. R. Morrow (CFO) | 1.8% | 360,000 |
| Retail Investors | Various | 75.7% | 15,140,000 |
Recent Share Price and Market Capitalization
As of the latest trading day, the share price of Acer Therapeutics Inc. (ACER) stands at $1.50. The market capitalization based on the current share price is calculated as follows:
- Shares Outstanding: 20,000,000
- Market Capitalization = Share Price × Shares Outstanding
- Market Capitalization = $1.50 × 20,000,000 = $30,000,000
Recent Changes in Share Ownership
In the most recent quarterly report, significant changes in share ownership have been noted:
| Change Type | Shareholder Name | Shares Added/Removed | New Percentage Ownership |
|---|---|---|---|
| Added | BlackRock, Inc. | 500,000 | 7.5% |
| Removed | Opus Point Partners Management, LLC | -400,000 | 5.2% |
| Added | The Vanguard Group, Inc. | 300,000 | 6.3% |
Founders and Executive Ownership
Key executives and their ownership stakes include:
| Executive Name | Position | Ownership Percentage |
|---|---|---|
| Dr. Chris D. Prior | CEO | 3.5% |
| David A. R. Morrow | CFO | 1.8% |
| Dr. Andrea M. M. W. S. M. P. Manalac | CCO | 1.2% |
Institutional Investor Trends
In 2023, institutional ownership trends indicate a gradual increase in investments from notable firms:
- Increased analysis and interest from large funds in the biotech sector.
- Focus on companies with innovative therapeutic approaches.
- Institutional investors owning more than 5% include prominent names like BlackRock and Vanguard.
Conclusion on Ownership Dynamics
Ownership dynamics in Acer Therapeutics Inc. (ACER) reflect a balance of institutional and retail investors, with a significant portion belonging to various institutional stakeholders. Recent trends and shifts signify potential implications for corporate governance and strategic initiatives moving forward.
Acer Therapeutics Inc. (ACER) Mission Statement
Company Overview
Company Overview
Acer Therapeutics Inc. (ACER) is a biotechnology company focused on the acquisition, development, and commercialization of novel therapeutics for patients with serious and life-threatening diseases. It primarily targets unmet medical needs in the field of rare diseases.
Mission Statement
The mission of Acer Therapeutics is to deliver innovative and effective therapies for patients suffering from serious and life-threatening diseases, with a commitment to providing solutions for conditions that are inadequately addressed by current treatments.
Core Values
-
Patient-Centric Approach: Prioritizing the needs and safety of patients in all aspects of development.
-
Innovation: Fostering creativity and scientific excellence in research and development.
-
Integrity: Upholding the highest ethical standards in all operations.
-
Collaboration: Working together with healthcare professionals, industry partners, and the patient community.
Recent Financial Data
- Patient-Centric Approach: Prioritizing the needs and safety of patients in all aspects of development.
- Innovation: Fostering creativity and scientific excellence in research and development.
- Integrity: Upholding the highest ethical standards in all operations.
- Collaboration: Working together with healthcare professionals, industry partners, and the patient community.
Recent Financial Data
For the fiscal year ending December 31, 2022, Acer Therapeutics reported the following financial data:
| Financial Metric | Amount (USD) |
|---|---|
| Revenue | $0.5 million |
| Net Loss | ($18.3 million) |
| R&D Expenses | $14 million |
| General and Administrative Expenses | $4.3 million |
| Cash and Cash Equivalents | $12.1 million |
Market Focus
Acer Therapeutics concentrates on various therapeutic areas, notably:
- Urea Cycle Disorders
- Diabetes Insipidus
- Inherited Metabolic Disorders
- Other rare diseases
Product Pipeline
Acer Therapeutics has a robust pipeline with several candidates in various stages of development:
| Product Name | Indication | Phase |
|---|---|---|
| ACER-001 | Urea Cycle Disorders | Phase 3 |
| ACER-002 | Diabetes Insipidus | Phase 2 |
| ACER-003 | Inherited Metabolic Disorders | Preclinical |
Partnerships and Collaborations
Acer Therapeutics engages in collaborations to enhance its research and clinical development:
- Collaboration with Academic Institutions: Partnering with universities for research.
- Industry Partnerships: Working with pharmaceutical companies for joint development.
- Patient Advocacy Groups: Collaborating to understand patient needs better.
Future Objectives
Acer Therapeutics aims to advance its product candidates and expand its pipeline through:
- Clinical Trials: Progressing existing trials and initiating new ones.
- Regulatory Approvals: Seeking FDA and EMA approvals for new therapies.
- Commercialization: Preparing for market launch of successful candidates.
How Acer Therapeutics Inc. (ACER) Works
Company Overview
Acer Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for serious rare diseases. The company operates under the ticker symbol ACER on the NASDAQ. As of October 2023, Acer Therapeutics is headquartered in Newton, Massachusetts.
Pipeline of Products
The company has multiple product candidates in its pipeline, specifically targeting rare diseases. Their lead product candidates include:
- ACER-001
- ACER-002
- ACER-003
Financial Performance Data
As of Q3 2023, Acer Therapeutics reported the following financial statistics:
| Financial Metric | Q3 2023 Amount | Q2 2023 Amount | Q1 2023 Amount |
|---|---|---|---|
| Revenue | $0.1 million | $0.2 million | $0.15 million |
| Net Loss | ($7.5 million) | ($6.8 million) | ($7.0 million) |
| Total Assets | $27.8 million | $30.1 million | $34.5 million |
| Cash Position | $15.2 million | $18.3 million | $22.0 million |
Market Capitalization
The market capitalization of Acer Therapeutics as of late October 2023 is approximately $31 million. This figure represents the total value of the company's outstanding shares.
Regulatory Approvals and Clinical Trials
Acer Therapeutics has been actively pursuing regulatory approvals for its product candidates. Key milestones include:
- ACER-001: Currently in Phase III clinical trials for Urea Cycle Disorders.
- ACER-002: Phase II trials targeting the treatment of Maple Syrup Urine Disease (MSUD).
- ACER-003: Undergoing preclinical studies focused on L-citrullinemia.
Partnerships and Collaborations
Acer Therapeutics has established several collaborations with other biopharmaceutical companies and research institutions. Key partnerships include:
- Collaboration with U.S. National Institutes of Health (NIH) for research on rare diseases.
- Partnership with Patient Advocacy Groups for awareness and clinical trial recruitment.
Stock Performance
The stock performance of Acer Therapeutics in 2023 has been characterized by fluctuations. Key stock metrics include:
| Date | Stock Price | Change (%) |
|---|---|---|
| January 2023 | $3.00 | - |
| April 2023 | $2.50 | -16.67% |
| July 2023 | $1.80 | -28.00% |
| October 2023 | $2.00 | 11.11% |
Investment and Funding
Acer Therapeutics has raised funds through various financing rounds to support its R&D efforts. Recent funding events include:
- Private placement of common stock raising $5 million in March 2023.
- Grant funding from FDA totaling $2 million for orphan disease research.
Insurance and Reimbursement
The reimbursement landscape for Acer Therapeutics' products is crucial for their commercialization strategy. Key points include:
- Focus on obtaining coverage for rare disease treatments from major insurers.
- Engagement with Medicare and Medicaid programs to secure patient access.
How Acer Therapeutics Inc. (ACER) Makes Money
Product Revenue
Acer Therapeutics focuses on developing and commercializing innovative therapeutics for serious rare diseases. The main revenue source is through the sales of its approved products. As of Q3 2023, Acer reported revenue of $3.2 million attributed to the sales of its primary product, Acer's lead drug, Acadia, for treating Urea Cycle Disorders.
Partnerships and Collaborations
Acer Therapeutics also generates revenue through collaborations with larger pharmaceutical companies. For instance, their alliance with Fresenius Kabi for the distribution of one of their drugs has shown to provide additional financial backing. The financial contribution from such collaborations was reported at approximately $1.5 million in 2023.
Grants and Funding
The company actively seeks grants and funding opportunities to support its research initiatives. In 2022, Acer received a grant from the National Institutes of Health (NIH) amounting to $800,000 to further their development of therapies for rare diseases.
| Revenue Source | 2022 Amount | 2023 Amount |
|---|---|---|
| Product Sales | $2.8 million | $3.2 million |
| Partnerships | $1.2 million | $1.5 million |
| Grants | $500,000 | $800,000 |
Clinical Trial Funding
Acer Therapeutics conducts various clinical trials, often receiving funding through outside investors or from the government. Their recent clinical trial for a new treatment received approximately $2 million in funding from private investors in 2023.
Cost Management Strategies
To maximize profitability, Acer has implemented cost management strategies. Their operating expenses decreased from $10 million in 2022 to $8 million in 2023 due to streamlined processes and a focus on essential R&D activities.
| Year | Operating Expenses | Overall Revenue |
|---|---|---|
| 2022 | $10 million | $5 million |
| 2023 | $8 million | $5.5 million |
Regulatory Approvals and Market Expansion
The company aims to expand its market reach by obtaining regulatory approvals for new treatments. The approval of their latest drug is projected to generate an additional $4 million in revenue by the end of 2024.
Market Performance and Stock Valuation
Acer Therapeutics' stock performance is indicative of its financial health. As of October 2023, ACER's stock price stands at $4.50 per share, giving it a market capitalization of approximately $45 million.
Acer Therapeutics Inc. (ACER) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support